52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

Emery, P, Vencovský, J, Sylwestrzak, A et al. (10 more authors) (2017) 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology, 56 (12). pp. 2093-2101. ISSN 1462-0324

Abstract

Metadata

Authors/Creators:
  • Emery, P
  • Vencovský, J
  • Sylwestrzak, A
  • Leszczyński, P
  • Porawska, W
  • Baranauskaite, A
  • Tseluyko, V
  • Zhdan, VM
  • Stasiuk, B
  • Milasiene, R
  • Barrera Rodriguez, AA
  • Cheong, SY
  • Ghil, J
Copyright, Publisher and Additional Information: © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Keywords: biosimilar, SB4, Benepali, etanercept, rheumatoid arthritis, biologics
Dates:
  • Published: 1 December 2017
  • Accepted: 26 August 2016
  • Published (online): 19 August 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 01 Sep 2016 09:47
Last Modified: 22 Jan 2018 10:22
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/rheumatology/kex269

Share / Export

Statistics